Katya (Ethinylestradiol, Gestodene)

Ethinylestradiol/Gestodene, the active ingredient in Katya, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy and helps regulate menstrual cycles in women of reproductive age.

GNH USA supplies Katya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Katya, a combined oral contraceptive, is used in the hormonal regulation of reproduction.

Contraception: Provides reliable prevention of pregnancy when taken as prescribed. Regulation of menstrual cycles: Helps achieve more predictable bleeding patterns. Acne management: May improve acne associated with hormonal fluctuations.

Katya may cause a range of adverse reactions. Most are mild and transient.

Common Side Effects: - Nausea or mild gastrointestinal upset - Breast tenderness or enlargement - Headache or migraine - Spotting or breakthrough bleeding - Weight gain or fluid retention - Mood changes or irritability

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Severe hypertension - Liver dysfunction or cholestatic jaundice - Allergic reactions (rash, angioedema, anaphylaxis) - Visual disturbances or eye pain

Before prescribing Katya, clinicians should evaluate individual risk factors and counsel patients on safe use.

Cardiovascular assessment: Review history of thrombosis, hypertension, or smoking. Liver function: Avoid in active liver disease or severe hepatic impairment. Smoking restriction: Advise women >35 years who smoke to discontinue use. Missed dose management: Provide clear instructions for handling forgotten tablets. Drug‑interaction review: Check concomitant medications that may reduce efficacy. Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Katya can interact with several medicines, altering its contraceptive effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, St. John's wort) – may markedly reduce hormone levels. - Certain antiretrovirals (e.g., efavirenz) – can diminish contraceptive efficacy. - High‑dose glucocorticoids – may increase risk of thrombotic events.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole) – may increase hormone concentrations. - Macrolide antibiotics (erythromycin, clarithromycin) – modestly raise plasma levels. - Selective serotonin reuptake inhibitors – may exacerbate mood‑related side effects.